JPH02191468A - Subcataneous terminal - Google Patents
Subcataneous terminalInfo
- Publication number
- JPH02191468A JPH02191468A JP1025184A JP2518489A JPH02191468A JP H02191468 A JPH02191468 A JP H02191468A JP 1025184 A JP1025184 A JP 1025184A JP 2518489 A JP2518489 A JP 2518489A JP H02191468 A JPH02191468 A JP H02191468A
- Authority
- JP
- Japan
- Prior art keywords
- injection
- subcutaneous
- living body
- main body
- subcutaneous terminal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002347 injection Methods 0.000 claims abstract description 171
- 239000007924 injection Substances 0.000 claims abstract description 171
- 238000007920 subcutaneous administration Methods 0.000 claims description 157
- 238000003825 pressing Methods 0.000 claims description 12
- 238000003780 insertion Methods 0.000 abstract description 32
- 230000037431 insertion Effects 0.000 abstract description 32
- 239000012530 fluid Substances 0.000 abstract description 13
- 238000002559 palpation Methods 0.000 abstract description 11
- 229920001971 elastomer Polymers 0.000 abstract description 4
- 238000001514 detection method Methods 0.000 description 63
- 210000001367 artery Anatomy 0.000 description 26
- 239000002246 antineoplastic agent Substances 0.000 description 18
- 229940041181 antineoplastic drug Drugs 0.000 description 16
- 239000007789 gas Substances 0.000 description 13
- 239000007788 liquid Substances 0.000 description 12
- 230000017531 blood circulation Effects 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 210000003240 portal vein Anatomy 0.000 description 9
- 238000010586 diagram Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 201000007270 liver cancer Diseases 0.000 description 8
- 208000014018 liver neoplasm Diseases 0.000 description 8
- 229920002379 silicone rubber Polymers 0.000 description 8
- 239000004945 silicone rubber Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000010355 oscillation Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 3
- 229910010293 ceramic material Inorganic materials 0.000 description 3
- -1 cisbratinum Chemical compound 0.000 description 3
- 235000019589 hardness Nutrition 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 239000007769 metal material Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 229930192392 Mitomycin Natural products 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 229910000599 Cr alloy Inorganic materials 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 229920006311 Urethane elastomer Polymers 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000002767 hepatic artery Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000005236 sound signal Effects 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
Landscapes
- Media Introduction/Drainage Providing Device (AREA)
Abstract
Description
【発明の詳細な説明】
［産業上の利用分野］
本発明は、たとえば末期癌患者の延命を目的とした抗癌
剤動脈注入、あるいはその他に生体内目的部位にインシ
ュリン、ヘパリン、ウロキナーゼや、各種ホルモン等の
薬剤の供給、または輸血等を行なうことを目的として、
患者の皮下に埋め込んで定置するとともに、注射針等を
用いて生体外からその注入部に設けられた針入部に針を
刺し込み、各種の流体の注入や輸血、または血液、体液
等の採取を行なう皮下端子に関する。[Detailed Description of the Invention] [Industrial Application Field] The present invention is applicable to, for example, intraarterial injection of anticancer drugs for the purpose of prolonging the life of terminal cancer patients, or other purposes such as injection of insulin, heparin, urokinase, various hormones, etc. into a target site in a living body. For the purpose of supplying drugs or blood transfusions, etc.
It is implanted under the patient's skin and placed in place, and the needle is inserted into the injection site from outside the body using a syringe needle, etc. to inject various fluids, transfuse blood, or collect blood, body fluids, etc. Regarding subcutaneous terminals.
［従来の技術］
従来、このような使用目的に使用する皮下端子として、
特開昭６１−２３４８７０号公報において示されるもの
や、特表昭６２−５０２７２９号公報に示されるものが
ある。特開昭６１−２３４８７０号公報において示され
る皮下端子は、シリコーンゴム等で形成された１個の針
入部を有してなるものである。また、特表昭６２−５０
２７２９号公報に示されるものは、２個の注入部を設け
て、その一方の注入部より血管等を閉塞するための気体
や液体を送り込み、他方の針入部より各種の薬剤の注入
を行なうようになっている。[Prior Art] Conventionally, as a subcutaneous terminal used for such purposes,
There are those shown in Japanese Patent Application Laid-Open No. 61-234870 and those shown in Japanese Patent Application Publication No. 62-502729. The subcutaneous terminal disclosed in Japanese Unexamined Patent Application Publication No. 61-234870 has one insertion portion made of silicone rubber or the like. In addition, Special Table of Showa 62-50
The device shown in Publication No. 2729 is equipped with two injection parts, one of which injects gas or liquid to occlude blood vessels, etc., and the other needle entry part injects various drugs. It has become.
［発明が解決しようとする課題］
しかしながら、前述した先行例のものにおいては、生体
内に埋設した皮下端子の注入部の位置確認を生体外から
容易に確認することができなかった。このため、各種の
薬液の注入、あるいは輸血、または血液や体液等の採取
時に注射針を注入部に刺通するのが困難であった。[Problems to be Solved by the Invention] However, in the prior art example described above, it was not possible to easily confirm the position of the injection part of the subcutaneous terminal embedded in the living body from outside the living body. For this reason, it has been difficult to pierce the injection site with a syringe needle when injecting various medicinal solutions, performing blood transfusions, or collecting blood, body fluids, and the like.
さらに、例えば末期肝臓癌患者に対する治療として、前
記２個の注入部を有する皮下端子を生体内に埋め込み、
一方の注入部にはこれに設けられた針入部から、総計動
脈を閉塞するバルーン等よりなる閉塞具に供給するだめ
の気体や液体を注入し、他方の注入部にはこれに設けら
れた針入部から固有肝動脈へ投与する抗癌剤の注入を行
なうといった治療方法の場合、生体外より各注入部を区
別することは困難であったため、よほど注意しないと本
来、抗癌剤の注入を行なうべき注入部に、誤って血管閉
塞を行なうための気体、あるいは液体を注入してしまう
というおそれがないではない。Furthermore, for example, as a treatment for a terminal stage liver cancer patient, a subcutaneous terminal having the two injection parts is implanted in a living body,
A gas or liquid is injected into one injection part from the needle insertion part provided therein to a occluding device such as a balloon that occludes the total artery, and the other injection part is filled with a needle provided therein. In the case of treatment methods such as injecting anticancer drugs into the proper hepatic artery from the entrance site, it is difficult to distinguish each injection site from outside the body. However, there is a risk of accidentally injecting gas or liquid to occlude the blood vessel.
また、上記使用方法以外にも、複数の注入部を有する皮
下端子を生体内に埋め込み、その各注入部に対して異な
る薬剤を別々に注入し、それぞれ異なる部位へこれらの
薬剤を送り込むといった場合においても、生体外から各
注入部を区別することは困難であった。In addition to the method described above, in cases where a subcutaneous terminal with multiple injection parts is implanted in a living body, different drugs are injected into each injection part separately, and these drugs are delivered to different sites. However, it was difficult to distinguish each injection site from outside the body.
本発明は上記欠点を解消すべくなされたもので、複数の
注入部を有して生体内に埋設される皮下端子の各注入部
の位置確認を生体外から容易に行なうことが可能な皮下
端子を提供することを目的とする。The present invention has been made to solve the above-mentioned drawbacks, and is a subcutaneous terminal that has a plurality of injection parts and is capable of easily confirming the position of each injection part of a subcutaneous terminal buried in a living body from outside the living body. The purpose is to provide
［課題を解決するための手段および作用コ上記課題を解
決するための第１の発明は、生体内に埋め込んで定置す
る皮下端子において、上記皮下端子の注入部の近傍の一
部ないし全部に、生体外表面から指で押圧することで、
その注入部の位置を体外に告知する告知手段を設けたも
のである。[Means and effects for solving the problem] A first invention for solving the above problem is a subcutaneous terminal to be implanted and fixed in a living body, in which a part or all of the vicinity of the injection part of the subcutaneous terminal is provided with: By pressing with your finger from the in vitro surface,
A notification means is provided to notify the outside of the body of the position of the injection part.
このような皮下端子においては、複数の注入部を有する
にも拘らず、生体外からその注入部の位置を知ることが
でき、各種流体等の注入や採取を誤りなく確実に行なう
ことができる。Although such a subcutaneous terminal has a plurality of injection parts, the position of the injection part can be known from outside the living body, and various fluids can be injected and collected without error.
第２の発明は、複数の注入部を有し、生体内に埋込んで
定置する皮下端子において、上記皮下端子の少なくとも
１つの注入１部、もしくはその近傍の一部ないし全部を
他と異なる形状で構成したものである。A second invention is a subcutaneous terminal having a plurality of injection parts and implanted and fixed in a living body, wherein at least one injection part of the subcutaneous terminal or a part or all of the vicinity thereof has a shape different from the others. It is composed of
このような皮下端子においては、複数の注入部を有する
にも拘らず、生体外から触診をすることで、各注入部の
位置確認が容易に行なえ、各種流体等の注入や採取を誤
りなく確実に行なうことができる。Although such subcutaneous terminals have multiple injection parts, the position of each injection part can be easily confirmed by palpation from outside the body, making it possible to inject and collect various fluids without error. can be done.
第３の発明は、複数の注入部を有し、生体内に埋め込ん
で定置する皮下端子において、上記皮下端子の注入部、
もしくはその近傍にそれぞれ弾性特性の異なる弾性部材
を設けたものである。A third invention provides a subcutaneous terminal that has a plurality of injection parts and is implanted and placed in a living body, the injection part of the above-mentioned subcutaneous terminal,
Alternatively, elastic members having different elastic properties are provided in the vicinity thereof.
このような皮下端子においては、複数の注入部を有する
にも拘らず、生体外から触診によりその注入部の位置を
確認でき、各種流体等の注入や採取を誤りなく確実に行
なうことができる。Although such a subcutaneous terminal has a plurality of injection parts, the position of the injection part can be confirmed by palpation from outside the body, and various fluids can be injected and collected without error.
［実施例］
第１図ないし第３図は本発明の第１の実施例を示すもの
である。皮下端子本体１は生体為害性の無い、高分子材
料、セラミック材料または金属材料で構成されている。[Embodiment] FIGS. 1 to 3 show a first embodiment of the present invention. The subcutaneous terminal main body 1 is made of a polymer material, a ceramic material, or a metal material that is not harmful to living organisms.
この皮下端子本体１には、生体外より注射針等により別
々の種類の注入を行なうための複数の注入部、つまり、
ＴＳｌの注入部２、第２の注入部３、ＴＳ３の注入部４
が設けられている。そして、この各注入部２，３．４に
は別々に注入孔が形成され、この各注入孔には、それぞ
れ注射針等を穿刺するシリコーンゴム等よりなる第１の
針入部５、第２の針入部６、第３の針入部７が設けられ
ている。この各針入部５，６．７は固定部材８ａ、Ｅ３
ｂ、３ｃによってそれぞれ皮下端子本体１とねじ込み手
段により固定されている。また、前記第１の注入部２、
第２の注入部３、第３の注入部４はこの皮下端子本体１
を生体内に埋込み後、これらの区別を生体外より触診す
ることで行なうため、その告知手段として、その付設付
近の皮下端子本体１の各部分がそれぞれ段差を付けて形
成されている。また、前記各注入部２゜３．４の下部に
は、これに連通して導入路１０ａ。This subcutaneous terminal main body 1 has a plurality of injection parts for performing different types of injections from outside the living body using injection needles, etc.
TSl injection part 2, second injection part 3, TS3 injection part 4
is provided. Injection holes are separately formed in each of the injection parts 2, 3.4, and each injection hole has a first insertion part 5 and a second insertion part made of silicone rubber or the like, into which an injection needle or the like is inserted. A needle insertion section 6 and a third needle insertion section 7 are provided. Each of the needle insertion portions 5, 6.7 is connected to the fixing member 8a, E3.
b and 3c are respectively fixed to the subcutaneous terminal main body 1 by screwing means. Further, the first injection part 2,
The second injection part 3 and the third injection part 4 are connected to this subcutaneous terminal main body 1.
After being implanted in a living body, these can be distinguished by palpation from outside the living body, so each part of the subcutaneous terminal main body 1 in the vicinity of its attachment is formed with a step, respectively, as a notification means. Further, at the lower part of each of the injection parts 2.degree. 3.4, there is an introduction passage 10a communicating therewith.
１０ｂ、ＩＯＣが形成されている。導入部１０ａについ
て図示していない。そして、これらを通じて注入された
各種薬剤や気体、液体等を後述するカテーテル等の導入
部材９ ａ ＊ ９ ｂ ＋ ９ ’に導びくよう
になっている。前記導入路１０ａ、１０ｂ。10b, IOC is formed. The introduction part 10a is not shown. Various drugs, gases, liquids, etc. injected through these are guided to an introduction member 9a*9b+9' such as a catheter, which will be described later. The introduction paths 10a, 10b.
１０ｃの端部には、前記導入部材’）ａ、９ｂ、９Ｃを
縫合糸９ｄ等により固定するための突出部１１ａ、ｌｌ
ｂ、ｌｌｃがそれぞれ設けられている。At the end of 10c, there are protrusions 11a and 11a for fixing the introduction members')a, 9b, and 9C with suture threads 9d, etc.
b and llc are provided, respectively.
また、皮下端子本体１の周縁には、生体内に埋込み後、
縫合糸等により定置するための縫合孔１３が設けられて
いる。In addition, on the periphery of the subcutaneous terminal main body 1, after implantation in a living body,
A suture hole 13 is provided for positioning with a suture thread or the like.
第３図は、この前記皮下端子を用いて、末期肝臓癌患者
の延命を行なう場合の例を示すものである。すなわち、
１３は生体皮膚組織、１４は肝臓、１５は胃十二指腸動
脈、１６は門脈、１７は総計動脈、１８は大動脈をそれ
ぞれ示している。前記皮下端子本体１を生体皮膚組織１
３の下部に埋入する。皮下端子本体１に接続された導入
部材９ｂは上記胃十二指腸動脈１５から先端を肝臓１４
に向けて挿入留置されている。前記導入部材９ｂには、
挿入補助や位置決めをするための節１９が設けられてい
る。そして他の導入部材９ａ、９ｃの先端は門脈１６、
総計動脈１７の血流を一時的に遮断し、胃十二指腸動脈
１５へ注入した抗癌剤が長時間、肝臓１４内に留るよう
に設けられたバルーン等よりなる閉塞具２０ａ、２０ｂ
に接続されている。これらを用いて抗癌剤を注入する方
法は、まず、前記第１の針入部５、および第３の針入部
７に、生体皮膚組織１３を介して刺通するシリンジ２１
等の針を用いて空気等の気体、あるいは水等の液体を注
入する。前記注入された気体、あるいは液体は導入部材
９ａ、９ｃを通り、前記バルーン等よりなる閉塞具２０
ａ、２０ｂを膨脹させ、門脈１６、総計動脈１７を閉塞
し各血流を遮断する。その後、シリンジ２１等の針を用
いて前記第２の針入部６にマイトマイシン、アドリアマ
イシン、シスブラティニュム、５−ＦＵ （以上は商品
名）等の抗癌剤を注入する。注入された前記抗癌剤は、
門脈１６、総計動脈１７の血流が遮断されているため、
胃十二指腸動脈１５を通り、肝臓１４内に長時間、とど
まることになる。抗癌剤の注入が終われば、第１の針入
部５、および第３の針入部７にシリンジ２１等の針を皮
膚組織１３を介して刺通し、閉塞具２０ａ、２Ｏｂ内に
注入した気体あるいは液体を排出すれば、門脈１６およ
び総計動脈１７の血流が再開される。FIG. 3 shows an example in which the subcutaneous terminal is used to prolong the life of a patient with terminal liver cancer. That is,
Reference numeral 13 indicates the living skin tissue, 14 the liver, 15 the gastroduodenal artery, 16 the portal vein, 17 the total artery, and 18 the aorta. The subcutaneous terminal main body 1 is attached to living body skin tissue 1
Embed it at the bottom of 3. The introduction member 9b connected to the subcutaneous terminal main body 1 connects the tip from the gastroduodenal artery 15 to the liver 14.
It is inserted and placed towards. The introduction member 9b includes:
A knot 19 is provided for assisting insertion and positioning. The tips of the other introducing members 9a and 9c are the portal vein 16,
Obturators 20a and 20b, which are comprised of balloons or the like, are provided to temporarily block the blood flow in the total artery 17 and allow the anticancer drug injected into the gastroduodenal artery 15 to remain in the liver 14 for a long time.
It is connected to the. In order to inject an anticancer drug using these, first, a syringe 21 is inserted through the living skin tissue 13 into the first needle insertion part 5 and the third needle insertion part 7.
Inject gas such as air or liquid such as water using a needle such as . The injected gas or liquid passes through the introduction members 9a and 9c, and passes through the obturator 20 such as the balloon.
a and 20b are inflated to occlude the portal vein 16 and total artery 17 to cut off each blood flow. Thereafter, an anticancer agent such as mitomycin, adriamycin, cisbratinum, 5-FU (all trade names) is injected into the second needle insertion part 6 using a needle such as a syringe 21. The injected anticancer drug is
Because the blood flow in the portal vein 16 and total artery 17 is blocked,
It passes through the gastroduodenal artery 15 and remains in the liver 14 for a long time. When the injection of the anticancer drug is finished, a needle such as a syringe 21 is inserted through the skin tissue 13 into the first needle insertion part 5 and the third needle insertion part 7, and the gas or liquid injected into the obturators 20a and 2Ob is discharged. Blood flow in the portal vein 16 and total artery 17 is then resumed.
そして、前記抗癌剤等の注入を行なうために、生体内に
埋入された皮下端子本体１の各注入部２゜３．４の位置
確認を生体外から行なうときは、生体皮膚組織１３を介
して皮下端子本体１に触診すれば、その各注入部２．３
．４は皮下端子本体１上で段差を有して設けられている
ので、容易に判別できその位置確認を正しく行なうこと
ができる。When confirming the position of each injection part 2° 3.4 of the subcutaneous terminal main body 1 implanted in a living body from outside the living body in order to inject the anticancer drug, etc., it is necessary to confirm the position of each injection part 2. By palpating the subcutaneous terminal body 1, each injection part 2.3
．． 4 is provided with a step on the subcutaneous terminal main body 1, so that it can be easily distinguished and its position can be confirmed correctly.
しかして、このように構成された皮下端子は、各注入部
２，３．４が皮下端子本体１に段差を有して設けられて
いるため、生体外から触診することにより容易に各々の
注入部２，３．４に設けられた針入部５，６．７の位置
の確認ができ、たとえば、本来、閉塞具２０ａ、２Ｃ１
ｂを膨脹させるべき気体を誤って胃十二指腸動脈１５へ
注入するといった事はなくなる。However, in the subcutaneous terminal configured in this way, each injection part 2, 3.4 is provided with a step on the subcutaneous terminal main body 1, so each injection can be easily performed by palpation from outside the living body. The position of the needle insertion part 5, 6.7 provided in the part 2, 3.4 can be confirmed, for example, the position of the needle insertion part 5, 6.7 provided in the part 2, 3.4 can be confirmed.
This eliminates the possibility of accidentally injecting the gas that should inflate b into the gastroduodenal artery 15.
第４図ないし第５図は本発明の第２の実施例を示すもの
である。前記第１の実施例と同様に生体為害性のない高
分子材料、セラミック材料、あるいは金属材料で構成さ
れた皮下端子本体２２には、生体外より注射針等により
各種注入を行なうための第１の注入部２３、第２の注入
部２４、第３の注入部２５が設けられており、この各注
入部２３゜２４．２５には上述したと同様に、それぞれ
注射針等の針入を行なうためのシリコーンゴム等よりな
る第１の針入部２６、第２の針入部２７、第３の針入部
２８が設けられている。さらに、これらの針入部２６，
２７．２８は前記第１の実施例と同様に固定部材２９ａ
、２９ｂ、２９ｃによってそれぞれ皮下端子本体２２に
ねじ込みにより固定されている。4 and 5 show a second embodiment of the present invention. Similar to the first embodiment, the subcutaneous terminal main body 22, which is made of a polymer material, ceramic material, or metal material that is not harmful to the living body, has a first injector for performing various injections from outside the living body using a syringe needle or the like. An injection part 23, a second injection part 24, and a third injection part 25 are provided, and a syringe needle or the like is inserted into each injection part 23, 24, and 25 in the same manner as described above. A first needle penetration part 26, a second penetration part 27, and a third penetration part 28 made of silicone rubber or the like are provided. Furthermore, these needle insertion parts 26,
27 and 28 are fixed members 29a as in the first embodiment.
, 29b, and 29c are fixed to the subcutaneous terminal main body 22 by screwing, respectively.
また、前記第１の注入部２３、第２の注入部２４、第３
の注入部２５の各針入部２６，２７．２８の近傍にはそ
の皮下端子本体２２を生体内に埋込み後、各注入部２３
，２４．２５の区別を生体外より触診することで行なう
ため、その各注入部２３．２４．２５の位置を告知する
手段として、突起部３０が、第１の注入部２３には１個
、第２の注入部２４には２個、第３の注入部２５には３
個設けられている。Further, the first injection part 23, the second injection part 24, the third injection part 23,
After implanting the subcutaneous terminal main body 22 in the living body, each injection part 23 is placed near each needle entry part 26, 27, 28 of the injection part 25.
. 2 in the second injection part 24 and 3 in the third injection part 25
There are several.
このように構成された皮下端子本体２２を用いて、末期
肝臓癌患者の延命を行なうには前記第１の実施例と同様
に、皮下端子本体２２を生体皮膚組織１３の下部に埋込
み設置し、皮下端子本体２２に接続された導入部材９ｂ
を前記第１の実施例で示した第３図のように胃十二指腸
動脈１５から先端を肝臓１４に向けて留置する。また、
閉塞具２０ａ、２０ｂが先端に設けられた導入部材９ａ
。In order to prolong the life of a patient with terminal liver cancer using the subcutaneous terminal main body 22 configured as described above, the subcutaneous terminal main body 22 is implanted and placed under the skin tissue 13 of the living body, as in the first embodiment. Introduction member 9b connected to subcutaneous terminal body 22
As shown in FIG. 3 shown in the first embodiment, the tube is placed from the gastroduodenal artery 15 with the distal end facing the liver 14. Also,
Introducing member 9a with obturators 20a and 20b provided at the tip
.
９Ｃを門脈１６、総計動脈１７に導びき、この閉塞具２
０ａ、２０ｂをそれぞれ装着する。そして、抗癌剤を注
入する方法も前記第１の実施例と同様に、まず、第１の
針入部２６、および第３の針入部２８に生体皮膚組織１
３を介し、シリンジ等の針を用いて空気等の気体、ある
いは水等の液体を注入し、閉塞具２０ａ、２０ｂを膨脹
させ、門脈１６、総計動脈１７を閉塞させ、各血流を遮
断する。その後、シリンジ等の針を用い前記第２の針入
部２７へ各種抗癌剤を注入すると、注入された抗癌剤は
門脈１６、総計動脈１７の血流が遮断されているため、
胃十二指腸動脈１５を通り、肝臓１４内に長時間とどま
ることとなる。また、抗癌剤の注入が終わり、前記閉塞
具２０ａ、２０ｂに注入した気体あるいは液体を排出す
る方法も前記第１の実施例と同様である。9C to the portal vein 16 and total artery 17, and this obturator 2
Attach 0a and 20b respectively. The method of injecting the anticancer drug is similar to that of the first embodiment. First, the living body skin tissue 1 is injected into the first needle insertion part 26 and the third needle insertion part 28.
3, a gas such as air or a liquid such as water is injected using a needle such as a syringe to inflate the obturators 20a and 20b, occlude the portal vein 16 and the total artery 17, and cut off each blood flow. do. After that, when various anticancer drugs are injected into the second needle insertion part 27 using a needle such as a syringe, the blood flow of the injected anticancer drugs in the portal vein 16 and total artery 17 is blocked, so that
It passes through the gastroduodenal artery 15 and remains in the liver 14 for a long time. Furthermore, the method for discharging the gas or liquid injected into the obturator 20a, 20b after the injection of the anticancer drug is completed is also the same as in the first embodiment.
そして、各種注入を行なうために、前記生体内に埋入さ
れた皮下端子本体２２の注入部２３，２４．２５の位置
確認を生体外から行なう時は、生体皮膚組織１３を介し
て皮下端子本体２２に触診すれば、各注入部２３．２４
．２５の近傍にはそれぞれ異なる個数の突起部３０が設
けられているので、これにより容易に各々の位置確認を
正しく行なうことができる。When the positions of the injection parts 23, 24, 25 of the subcutaneous terminal main body 22 implanted in the living body are confirmed from outside the living body in order to perform various injections, the subcutaneous terminal main body is inserted through the living body's skin tissue 13. 22, each injection site 23.24
．． Since different numbers of protrusions 30 are provided in the vicinity of 25, each position can be easily and correctly confirmed.
このように各注入部２３，２４．２５はそのの近傍に異
なる個数の突起部３０がそれぞれ設けられているため、
生体外から触診することにより容易に判別できるほか、
前記第１の実施例の場合と同様の効果を有する。その他
の構成や作用については前記第１の実施例の場合と同様
である。In this way, since each injection part 23, 24, 25 is provided with a different number of protrusions 30 in the vicinity thereof,
It can be easily identified by palpation from outside the body, and
It has the same effect as the first embodiment. The other configurations and operations are the same as in the first embodiment.
第６図および第７図は本発明の第３の実施例を示すもの
である。この実施例は前記第２の実施例で述べた生体外
より各注入部３１．３３．３５の位置確認を行なうため
に設けた告知手段の突起部３０に代わって、その針入部
２６．２７．２８の固定部材の形状をそれぞれ異なるよ
うにしたものである。すなわち、第１の注入部３１は円
状の第１の固定部材３２が、第２の注入部３３には四角
形の第２の固定部材３４が、第３の注入部３５には三角
形の第３の固定部材３６が設けられ、前記第１、第２の
実施例と同様にシリコーンゴム等よりなる各針入部２６
，２７．２８を皮下端子本体３７とねじ込みにより固定
している。その他の構成については前記第２の実施例の
場合と同様である。FIGS. 6 and 7 show a third embodiment of the present invention. In this embodiment, instead of the protrusion 30 of the notification means provided for confirming the position of each injection part 31, 33, 35 from outside the living body described in the second embodiment, the needle insertion part 26, 27. The 28 fixing members have different shapes. That is, the first injection part 31 has a circular first fixing member 32, the second injection part 33 has a rectangular second fixing member 34, and the third injection part 35 has a triangular third fixing member 32. A fixing member 36 is provided, and each needle insertion part 26 made of silicone rubber or the like is provided as in the first and second embodiments.
, 27 and 28 are fixed to the subcutaneous terminal main body 37 by screwing. The other configurations are the same as in the second embodiment.
このように構成された皮下端子本体３７は、前記第１、
第２の実施例で述べたように、末期肝臓癌患者の延命等
に適応することができる。そして、各注入部の位置確認
を生体外から行なうときも、前記第１、第２の実施例で
述べたように、生体皮膚組織１３を介して皮下端子本体
３７に触診すれば、各注入部３１，３３．３５には前記
異なる形状の第１の固定部材３２、第２の固定部材３４
、第３の固定部材３６が設けられているため、容易に各
々の注入部３１，３３．３５の位置確認を正しく行なう
ことができる。The subcutaneous terminal main body 37 configured in this way has the first,
As described in the second embodiment, it can be applied to extend the life of patients with terminal liver cancer. When confirming the position of each injection part from outside the body, as described in the first and second embodiments, if the subcutaneous terminal main body 37 is palpated through the living body's skin tissue 13, each injection part can be confirmed. 31, 33, and 35, the first fixing member 32 and the second fixing member 34 of different shapes are shown.
Since the third fixing member 36 is provided, it is possible to easily and correctly confirm the position of each injection part 31, 33, 35.
しかして、このように構成された皮下端子によれば、各
注入部３１，３３．３５に設けられた固定部材３２，３
４．３６の形状が各々異なっているため、生体外から触
診することにより容易に各々の注入部３１，３３．３５
に設けられた針入部２６．２７．２８の位置確認ができ
るほか、前記第１、第２の実施例の場合と同様の効果を
有する。According to the subcutaneous terminal configured in this way, the fixing members 32, 3 provided in each injection part 31, 33, 35.
4.36 have different shapes, each injection part 31, 33.35 can be easily identified by palpation from outside the living body.
In addition to being able to confirm the position of the needle penetration parts 26, 27, and 28 provided in the 1st and 2nd embodiments, the same effects as in the first and second embodiments are obtained.
第８図ないし第１２図は本発明の第４の実施例を示すも
のである。この皮下端子本体４１は生体為害性のない高
分子材料、セラミック材料、金属材料等で形成されてい
る。また、皮下端子本体４１には生体外より注射針等に
より各種注入を行なうための注入部が設けられている。8 to 12 show a fourth embodiment of the present invention. The subcutaneous terminal main body 41 is made of a polymeric material, a ceramic material, a metal material, etc. that is not harmful to living organisms. Further, the subcutaneous terminal main body 41 is provided with an injection part for performing various injections from outside the living body using a syringe needle or the like.
この注入部は皮下端子本体４１に注入孔４２を設けると
ともに、この注入孔４２に対して注射針等の針を刺通で
きるシリコーンゴム等の部材よりなる針入部４３を設け
て構成されている。この針入部４３は、固定部材４４に
よって皮下端子本体４１にねじ込み固定されている。ま
た、皮下端子本体４１の上部における注入孔４２の周囲
には、この皮下端子本体４１を生体内に埋入後、注入孔
４２の位置確認を生体外から押圧することで検知するた
めのスイッチ的機能を有する感圧抵抗体４５が貼むされ
ている。感圧抵抗体４５には、たとえば東芝シリコーン
（株）製の「シルタッチ」、伯東社製の「力覚抵抗体」
、二足ベルト社製の「ツーデックス」、横浜ゴム（株）
製の「感圧導電性シリコーンゴムシート（ＧＳ５７−７
Ｒ３Ｃ）Ｊ （いずれも商品名）等の感圧導電インク
や感圧導電ゴムからシート状に形成したものが用いられ
る。そして、全面的に圧力を検知できるようになってい
る。その具体例としては第１０図に示すように構成され
る。This injection part is constructed by providing an injection hole 42 in the subcutaneous terminal main body 41 and providing a needle insertion part 43 made of a material such as silicone rubber through which a needle such as an injection needle can be inserted into the injection hole 42. This needle insertion part 43 is screwed and fixed to the subcutaneous terminal main body 41 by a fixing member 44. Further, around the injection hole 42 in the upper part of the subcutaneous terminal main body 41, a switch is installed to confirm the position of the injection hole 42 by pressing it from outside the living body after the subcutaneous terminal main body 41 is implanted in the living body. A functional pressure sensitive resistor 45 is pasted. The pressure-sensitive resistor 45 may be, for example, "Siltouch" manufactured by Toshiba Silicone Co., Ltd. or "Force-sensitive resistor" manufactured by Hakutosha.
, "Two Dex" manufactured by Nisoku Belt Co., Ltd., Yokohama Rubber Co., Ltd.
“Pressure-sensitive conductive silicone rubber sheet (GS57-7
A sheet formed from pressure-sensitive conductive ink or pressure-sensitive conductive rubber such as R3C)J (all trade names) is used. It is also possible to detect pressure across the entire surface. A specific example thereof is constructed as shown in FIG.
すなわち、くし型電極４６を上面に印刷した第１のフィ
ルムシート４７に、下面に感圧導電インク４８を印刷し
た第２のフィルムシート４９を貼り合せたものである。That is, a second film sheet 49 having pressure-sensitive conductive ink 48 printed on the bottom surface is bonded to a first film sheet 47 having comb-shaped electrodes 46 printed on the top surface.
また、感圧抵抗体４５からは、リード線５０が導出して
いる。なお、この感圧抵抗体４５の代わりに押圧する間
、通電可能となるタクトスイッチ等を用いてもよい。Further, a lead wire 50 is led out from the pressure sensitive resistor 45. Note that instead of this pressure-sensitive resistor 45, a tact switch or the like that can be energized while being pressed may be used.
一方、皮下端子本体４１の上部には上方に開口する２つ
の穴部５４．５５が形成され、これには前記感圧抵抗体
４５で検知した圧力を生体外に光の信号として送るだめ
の告知手段であって、かつ発光素子としての第１のＬＥ
Ｄ５１と第２のＬＥＤ５２が別々に装填して設けられ、
さらに、その内側部分には電源５３ａおよび抵抗５３ｂ
が埋設されている。そして、これらの感圧抵抗体４５、
第１のＬＥＤ５１、第２のＬＥＤ５２、電源５３ａ１抵
抗５３ｂは第１１図に示すように接続された電気回路を
（１１１成する。On the other hand, two holes 54 and 55 opening upward are formed in the upper part of the subcutaneous terminal main body 41, and there are notifications for transmitting the pressure detected by the pressure sensitive resistor 45 outside the living body as a light signal. A first LE as a means and a light emitting element
D51 and the second LED 52 are separately loaded and provided,
Furthermore, a power supply 53a and a resistor 53b are provided in the inner part.
is buried. And these pressure sensitive resistors 45,
The first LED 51, the second LED 52, the power source 53a, and the resistor 53b form an electrical circuit (111) connected as shown in FIG.
また、皮下端子本体４１の下部には、前記注入孔４２に
連通し、注入された各種流体をカテーテル等の導入部材
５６に導びくための貫通孔５７が設けられている。そし
て、この貫通孔５７の外端に対応して導入部材５６を固
定するための突出部５９が設けられている。導入部材５
６はその一端部分を突出部５９に被嵌するとともに固定
糸５８により締結して接続される。さらに、皮下端子本
体４１の下部周縁にはその皮下端子本体４１の生体内に
埋入後に縫合糸等により定置するために使用する複数の
縫合孔６０が設けられている。Furthermore, a through hole 57 is provided in the lower part of the subcutaneous terminal main body 41 to communicate with the injection hole 42 and to guide the various injected fluids to an introduction member 56 such as a catheter. A protrusion 59 for fixing the introduction member 56 is provided corresponding to the outer end of the through hole 57. Introduction member 5
6 is connected by fitting one end portion into the protruding portion 59 and fastening it with a fixing thread 58. Furthermore, a plurality of suture holes 60 are provided at the lower peripheral edge of the subcutaneous terminal main body 41 to be used for fixing the subcutaneous terminal main body 41 in place with sutures or the like after implantation in a living body.
次に、この実施例の皮下端子の使用方法について説明す
る。まず、第１２図で示すように生体皮膚組織６１の下
部に、前記皮下端子本体４１を埋め込む。皮下端子本体
４１に接続されたカテーテル等の導入部材５６は、各種
薬剤等の注入を目的とする血管６２等に挿入され、縫合
糸６３により固定される。Next, a method of using the subcutaneous terminal of this embodiment will be explained. First, as shown in FIG. 12, the subcutaneous terminal main body 41 is embedded in the lower part of the living skin tissue 61. An introduction member 56 such as a catheter connected to the subcutaneous terminal main body 41 is inserted into a blood vessel 62 or the like for injecting various drugs, etc., and fixed with a suture thread 63.
一方、生体外より生体内の皮下端子本体４１の注入孔４
２の位置を確認するには、指等により生体皮膚組織６１
を介して皮下端子本体４１の上部の注入孔４２の周囲部
を押圧する。すると、注入孔４２の周囲にある感圧抵抗
体４５は指等で押圧した圧力を受けて電気抵抗が下がる
。しかして、第１１図に示した電気回路に電流が流れる
ことになる。よって、第１のＬＥＤ５１、および第２の
ＬＥＤ５２がそれぞれ点灯することになる。On the other hand, the injection hole 4 of the subcutaneous terminal main body 41 in the living body rather than outside the living body
To confirm the position of 2, touch the biological skin tissue 61 with your finger, etc.
The surrounding area of the injection hole 42 in the upper part of the subcutaneous terminal main body 41 is pressed through. Then, the pressure sensitive resistor 45 around the injection hole 42 receives pressure from a finger or the like, and its electrical resistance decreases. Therefore, current will flow through the electric circuit shown in FIG. Therefore, the first LED 51 and the second LED 52 are each turned on.
ところで、一般に、生体皮膚組織６１は透光性を有して
いるため、第１のＬＥＤ５１、第２のしＥＤ５２の光は
その生体皮膚組織６１を介し生体外に透過し、術者はそ
の第１のＬＥＤ５１と、第２のＬＥＤ５２の光を目視に
より確認することができる。そして、この第１のＬＥＤ
５１と第２のＬＥＤ５２は皮下端子本体４１の注入孔２
を挟む両端の位置にそれぞれ設けているため、生体外よ
り第１のＬＥＤ５１、第２のＬＥＤ５２の光を確認する
ことで、皮下端子本体４１の注入孔４２の位置を知るこ
とが可能となる。By the way, since the living body skin tissue 61 generally has translucency, the light from the first LED 51 and the second LED 52 is transmitted outside the living body through the living body skin tissue 61, and the operator can The light from the first LED 51 and the second LED 52 can be visually confirmed. And this first LED
51 and the second LED 52 are the injection hole 2 of the subcutaneous terminal main body 41.
Since they are provided at both ends of the subcutaneous terminal body 41, it is possible to know the position of the injection hole 42 of the subcutaneous terminal body 41 by checking the light from the first LED 51 and the second LED 52 from outside the living body.
そこで、皮下端子本体４１の注入孔４２の位置を確認し
て、生体外よりシリンジ６４等の針６５を生体皮膚組織
６１を介して刺通し、注入孔４２の針入部４３に刺し込
む。そして、このシリンジ６４等を通じて各種薬剤等の
流体６６を注入すれば、この流体６６は、導入部材５６
を通じて目的部位に送り込まれる。Therefore, the position of the injection hole 42 of the subcutaneous terminal main body 41 is confirmed, and a needle 65 such as a syringe 64 is pierced through the living body's skin tissue 61 from outside the living body and inserted into the needle insertion part 43 of the injection hole 42 . When a fluid 66 such as various drugs is injected through the syringe 64 or the like, this fluid 66 is transferred to the introduction member 56.
It is sent to the target area through.
このように構成された皮下端子は、皮下端子本体４１の
上部にある注入孔４２の周囲に感圧抵抗体４５があり、
また、皮下端子本体４１に設けられた穴部５４．５５に
は第１のＬＥＤ５１と第２のＬＥＤ５２、これを点灯駆
動する電源５３ａが埋設されているため、生体外より指
等で生体皮膚組織６１を介して皮下端子本体４１上部の
注入孔４２の周囲を押圧することで、第１のＬＥＤ５１
と第２のＬＥＤ５２を点灯し、生体外より容易に注入孔
４２の位置を確認することが可能となる。The subcutaneous terminal configured in this way has a pressure sensitive resistor 45 around the injection hole 42 in the upper part of the subcutaneous terminal main body 41,
In addition, since the first LED 51, the second LED 52, and a power source 53a for lighting and driving the first LED 51 and the second LED 52 are buried in the holes 54 and 55 provided in the subcutaneous terminal main body 41, it is possible to remove the living skin tissue from outside the living body using a finger or the like. By pressing around the injection hole 42 on the upper part of the subcutaneous terminal main body 41 via 61, the first LED 51
By lighting up the second LED 52, it becomes possible to easily confirm the position of the injection hole 42 from outside the living body.
また、薬剤等の各種流体の注入を正確に行なえるように
なる。Moreover, it becomes possible to accurately inject various fluids such as medicines.
なお、前記感圧抵抗体４５を注入孔４２に設けられた固
定部材４４の上面にも貼着する構成であってもよい。Note that the pressure sensitive resistor 45 may also be attached to the upper surface of the fixing member 44 provided in the injection hole 42.
第１３図ないし第１５図は本発明の第５の実施例を示す
ものである。13 to 15 show a fifth embodiment of the present invention.
この実施例ではその皮下端子本体６７の上部に、２個の
注入孔６８ａ、６８ｂを設けたものである。In this embodiment, two injection holes 68a and 68b are provided in the upper part of the subcutaneous terminal main body 67.
すなわち、第１の注入孔６８ａと第２の注入孔６８ｂに
は前記第４の実施例と同様にシリコーンゴム等よりなる
２つの針入部、つまり、第１の針入部６９ａ１第２の針
入部６９ｂを設け、これらは固定部材７０ａ、７０ｂを
それぞれ皮下端子本体６７にねじ込みにより固定されて
いる。また、各々の注入孔６８ａ、６８ｂの下部には第
１の貫通孔７１ａと第２の貫通孔７１ｂが設けられてい
る。That is, the first injection hole 68a and the second injection hole 68b have two injection parts made of silicone rubber or the like, as in the fourth embodiment, that is, a first injection part 69a and a second injection part 69b. are provided, and these are fixed by screwing fixing members 70a and 70b to the subcutaneous terminal main body 67, respectively. Further, a first through hole 71a and a second through hole 71b are provided at the bottom of each injection hole 68a, 68b.
各貫通孔７１ａ、７１ｂの外端部は上記実施例と同様に
固定系５８により突出部７３ａ、７３ｂに固定した導入
部材７２ａ、７２ｂに接続されている。The outer ends of each through hole 71a, 71b are connected to introduction members 72a, 72b fixed to protrusions 73a, 73b by a fixing system 58, as in the above embodiment.
また、皮下端子本体６７の下部周縁にはその皮下端子本
体６７を生体内に埋入後、縫合糸等により定置するため
の複数の縫合孔６０が設けられている。Further, a plurality of suture holes 60 are provided at the lower peripheral edge of the subcutaneous terminal main body 67 for fixing the subcutaneous terminal main body 67 in place with a suture thread or the like after implantation in a living body.
さらに、皮下端子本体６７の上部において、各注入孔６
８ａ、６８ｂの周囲には、皮下端子本体６７を生体内に
埋入後、各注入孔６８ａ、６８ｂの位置確認を生体外か
ら押圧することで検知するだめの、スイッチ的機能を果
たす上記同様の構成からなる感圧抵抗体７４が貼着され
ている。さらに、皮下端子本体６７の上部において、各
注入孔６８ａ、６８ｂに並んだ近傍には告知手段として
、発光素子、すなわち、第１のＬＥＤ７５ａ、および第
２のＬＥＤ７５ｂが図示しない穴部に、図示しない電源
や抵抗とともに第４の実施例の場合と同様に埋設され、
これらは第１１図で示すものと同様に接続されて電気回
路を構成している。なお、第４の実施例で述べたように
感圧抵抗体７４はタクトスイッチ等でもよい。Furthermore, in the upper part of the subcutaneous terminal main body 67, each injection hole 6
Around the subcutaneous terminals 8a and 68b, after the subcutaneous terminal main body 67 is implanted in the living body, the positions of the respective injection holes 68a and 68b can be detected by pressing them from outside the living body. A pressure sensitive resistor 74 consisting of the following structure is attached. Furthermore, in the upper part of the subcutaneous terminal main body 67, in the vicinity of each of the injection holes 68a and 68b, light emitting elements, that is, a first LED 75a and a second LED 75b are placed in hole portions (not shown) as notification means. It is buried along with the power supply and resistor as in the fourth embodiment,
These are connected in the same way as shown in FIG. 11 to form an electric circuit. Note that, as described in the fourth embodiment, the pressure sensitive resistor 74 may be a tact switch or the like.
そして、第１のＬＥＤ７５ａは第１の注入孔６８ａの近
傍、第２のＬＥＤ７５ｂは第２の注入孔６８ｂの近傍に
それぞれ設けられている。また、第１のＬＥＤ７５ａと
第２のＬＥＤ７５ｂとは異なる色で発光する。たとえば
、第１のＬＥＤ７５ａは赤色を、第２のＬＥＤ７５ｂは
緑色に発光するものとする。The first LED 75a is provided near the first injection hole 68a, and the second LED 75b is provided near the second injection hole 68b. Further, the first LED 75a and the second LED 75b emit light in different colors. For example, assume that the first LED 75a emits red light and the second LED 75b emits green light.
次に、この実施例の皮下端子を用いて、末期肝臓癌患者
の治療を行なう例を説明する。第１５図において、６１
は生体皮膚組織、７６は肝臓、７７は胃十二指腸動脈、
７８は門脈、７９は総計動脈、８０は大動脈を示す。Next, an example of treating a terminal stage liver cancer patient using the subcutaneous terminal of this embodiment will be described. In Figure 15, 61
is living skin tissue, 76 is liver, 77 is gastroduodenal artery,
78 indicates the portal vein, 79 indicates the total artery, and 80 indicates the aorta.
そこで、まず、上記皮下端子本体６７を生体皮膚組織６
１の下部に埋入する。皮下端子本体６７に接続されたカ
テーテルである一方の導入部材７２ｂは上記胃十二指腸
動脈７７から先端を肝臓７６に向けて挿入留置されてい
る。導入部材７２ｂには、挿入補助や位置決めをするた
めの節８１が設けられている。そして、もう一方の導入
部材７２ａの先端には総計動脈７９の血流を一時的に遮
断し、胃十二指腸動脈７７へ注入した抗癌剤が、長時間
肝臓７６内に留まるようにするために設けられたバルー
ン等よりなる閉塞具８２（これについては実願昭６２−
１４４５１２号出願明細書参照）が接続され、総計動脈
７９に装着されている。Therefore, first, the subcutaneous terminal main body 67 is attached to the biological skin tissue 6.
Embed it at the bottom of 1. One introducing member 72b, which is a catheter connected to the subcutaneous terminal main body 67, is inserted and left in place from the gastroduodenal artery 77 with its tip directed toward the liver 76. The introduction member 72b is provided with a knot 81 for assisting insertion and positioning. A tip of the other introduction member 72a is provided in order to temporarily block the blood flow in the total artery 79 so that the anticancer drug injected into the gastroduodenal artery 77 remains in the liver 76 for a long time. Obturator 82 consisting of a balloon, etc.
144,512) is connected and attached to the total artery 79.
そして、この状態で生体外より、生体内にある皮下端子
本体６７の各注入孔６８ａ、６８ｂの位置の確認、およ
び判別を行なうには、前記第４の実施例と同様、指等に
より生体皮膚組織６１を介し、皮下端子本体６７の上部
の各注入孔６８ａ、６８ｂの周囲部を押圧する。前述し
たと同様に、皮下端子本体６７の上部台注入孔６８ａ、
６８ｂの周囲部には、スイッチ的機能を果たす感圧抵抗
体７４があり、さらに、皮下端子本体６７の各注入孔６
８ａ、６８ｂの近傍には、第１のＬＥＤ７５ａと第２の
ＬＥＤ７５ｂが対応して配置されている。In this state, in order to confirm and distinguish the positions of the injection holes 68a and 68b of the subcutaneous terminal main body 67 in the living body from outside the living body, the injection holes 68a and 68b in the subcutaneous terminal body 67 inside the living body can be confirmed and distinguished by touching the living body's skin with a finger or the like, as in the fourth embodiment. The surrounding portions of the injection holes 68a and 68b in the upper part of the subcutaneous terminal main body 67 are pressed through the tissue 61. As described above, the upper base injection hole 68a of the subcutaneous terminal main body 67,
There is a pressure-sensitive resistor 74 around the subcutaneous terminal body 68b, which functions as a switch, and each injection hole 6 of the subcutaneous terminal body 67.
A first LED 75a and a second LED 75b are arranged in the vicinity of 8a and 68b in a corresponding manner.
しかして、指等で皮下端子本体６７上部の各注入孔６８
ａ、６８ｂの周囲部を押圧することで、第１のＬＥＤ７
５ａ、および第２のＬＥＤ７５ｂはそれぞれ点灯するこ
とになる。よって、生体皮膚組織６１を介し生体外より
第１のＬＥＤ７５ａ。Then, use your finger or the like to insert each injection hole 68 in the upper part of the subcutaneous terminal main body 67.
By pressing the peripheral parts of a and 68b, the first LED 7
5a and the second LED 75b are each turned on. Therefore, the first LED 75a is emitted from outside the living body through the living body skin tissue 61.
第２のＬＥＤ７５ｂの光を目視により確認することがで
きる。The light from the second LED 75b can be visually confirmed.
さらに、各ＬＥＤ７５ａ、７５ｂは異なる色の光、つま
り、第１のＬＥＤ７５ａは赤色の光を、第２のＬＥＤ７
５ｂは緑色の光を放つ。したがって、生体外より第１の
ＬＥＤ７５ａと第２のＬＥＤ７５ｂの光を別々に確認す
ることで、皮下端子本体６７の各注入孔６８ａ、６８ｂ
の位置の確認、および判別が可能となる。Further, each LED 75a, 75b emits light of a different color, that is, the first LED 75a emits red light, and the second LED 75a emits red light.
5b emits green light. Therefore, by separately confirming the light of the first LED 75a and the second LED 75b from outside the living body, each injection hole 68a, 68b of the subcutaneous terminal main body 67 can be
It becomes possible to confirm and distinguish the position of
そして、皮下端子本体６７の各注入孔６８ａ。And each injection hole 68a of the subcutaneous terminal main body 67.
６８ｂの位置が確認できたら、まず、第１のＬＥＤ７５
ａの近傍の第１の注入孔６８ａに設けられた第１の針入
部６９ａに、生体皮膚組織６１を介し、シリンジ６４の
針６５を用いて空気等の気体、あるいは水等の液体から
なる流体６６を注入する。After confirming the position of 68b, first turn on the first LED 75.
A fluid consisting of a gas such as air or a liquid such as water is injected into the first needle insertion part 69a provided in the first injection hole 68a near a through the living body skin tissue 61 using the needle 65 of the syringe 64. Inject 66.
前記注入された流体は導入部材７２ａを通り、前記バル
ーン等よりなる閉寒具８２を膨脹させ、総計動脈７９を
閉塞し血流を遮断する。その後、同様にシリンジの針を
用いて、第２のＬＥＤ７５ｂ近傍の第２の注入孔６８ｂ
に設けられた第２の針入部６９ｂにマイトマイシン、ア
ドリアマイシン、シスブラティニュム、５−ＦＵ （以
上は商品名）等の抗癌剤を注入する。注入された前記抗
癌剤は、総計動脈７９の血流が遮断されているため、肝
臓７６内に長時間留まることになる。抗癌剤の注入が終
われば、第１の針入部６９ａにシリンジの針を生体皮膚
組織６１を介して針入し、閉塞部８２内に注入した気体
あるいは液体等の流体を排出すれば、総計動脈７９の血
流は再開する。The injected fluid passes through the introduction member 72a and inflates the cold-closing device 82 made of the balloon or the like, occluding the total artery 79 and cutting off blood flow. Thereafter, using the syringe needle in the same manner, the second injection hole 68b near the second LED 75b is inserted.
An anticancer agent such as mitomycin, adriamycin, cisbratinum, or 5-FU (the above are trade names) is injected into the second needle insertion part 69b provided in the second needle insertion part 69b. The injected anticancer drug remains in the liver 76 for a long time because the blood flow through the total artery 79 is blocked. When the injection of the anticancer drug is finished, the needle of the syringe is inserted into the first needle insertion part 69a through the biological skin tissue 61, and the fluid such as gas or liquid injected into the occluded part 82 is discharged, and the total artery 79 is discharged. blood flow resumes.
しかして、この実施例の皮下端子は、皮下端子本体６７
の上部にある各注入孔６８ａ、６８ｂの周囲部に感圧抵
抗体７４が、また、皮下端子本体６７の各注入孔６８ａ
、６８ｂの近傍に設けられた穴部には、各々異なる色の
光を放つ第１のＬＥＤ７５ａと第２のＬＥＤ７５ｂがあ
り、これが、生体外より指等で生体皮膚組織６１を介し
て、皮下端子本体６７上部の各注入孔６８ａ、６８ｂの
周囲部を押圧することで、それぞれが点灯する。Therefore, the subcutaneous terminal of this embodiment has a subcutaneous terminal main body 67.
A pressure sensitive resistor 74 is placed around each injection hole 68a, 68b in the upper part of the subcutaneous terminal main body 67.
, 68b, there are a first LED 75a and a second LED 75b, each of which emits light of a different color. By pressing the periphery of each of the injection holes 68a and 68b on the upper part of the main body 67, each of them lights up.
しかして、生体外より容易にその各注入孔６８ａ。Therefore, each injection hole 68a can be easily removed from the living body.
６８ｂの位置を確認、判別することが可能となる。It becomes possible to confirm and determine the position of 68b.
よって、本来、閉塞具８２を膨脹させるべき気体、液体
等を誤って胃十二指腸動脈７７へ注入するおそれもなく
なる他、前記第４の実施例と同等の作用効果を奏する。Therefore, there is no fear that the gas, liquid, etc. that should normally inflate the obturator 82 will be accidentally injected into the gastroduodenal artery 77, and the same effects as in the fourth embodiment can be achieved.
第１６図ないし第１８図は本発明の第６の実施例を示す
ものである。この実施例は上記第５の実施例で述べた、
皮下端子本体４３における注入部近傍の穴部に埋設した
各ＬＥＤ７５ａ、７５ｂ。16 to 18 show a sixth embodiment of the present invention. This embodiment is as described in the fifth embodiment above.
Each LED 75a, 75b is embedded in a hole near the injection part in the subcutaneous terminal main body 43.
電源、抵抗、および皮下端子本体６７の上部の注入孔６
８ａ、６８ｂの周囲に貼着した感圧抵抗体７４の代わり
に、その皮下端子本体８３に設けた第１の注入孔６８ａ
、第２の注入孔６８ｂのそれぞれに対応して、皮下端子
本体８３の図示しない穴部に埋設して第１の検出部８４
ａ１第２の検出部８４ｂを設けたものである。すなわち
、第１の注入孔６８ａに対応した第１の検出部８４ａは
第１７図に示すような電気回路に構成されており、後述
するようにスイッチ的機能を果たす。すなわち、第１の
感圧抵抗体８５ａは第１の電源８６８１第１の抵抗８７
ａに接続され、さらに、第１の発振回路８８ａと、この
信号を増幅するだめの第１のアンプ８９ａと、増幅され
た信号を音の信号として生体外に送るための告知手段と
しての第１のスピーカ９０ａがそれぞれ接続されている
。Power source, resistor, and injection hole 6 on the top of the subcutaneous terminal body 67
A first injection hole 68a provided in the subcutaneous terminal body 83 instead of the pressure sensitive resistor 74 attached around the subcutaneous terminal body 8a and 68b.
, the first detection part 84 is embedded in a hole (not shown) of the subcutaneous terminal main body 83 corresponding to each of the second injection holes 68b.
a1 A second detection section 84b is provided. That is, the first detection section 84a corresponding to the first injection hole 68a is configured as an electric circuit as shown in FIG. 17, and performs a switch-like function as described later. That is, the first pressure sensitive resistor 85a is connected to the first power source 8681 and the first resistor 87.
a, and further includes a first oscillation circuit 88a, a first amplifier 89a for amplifying this signal, and a first amplifier 89a as a notification means for sending the amplified signal outside the living body as a sound signal. speakers 90a are connected to each of the speakers 90a.
また、同様に第２の注入孔６８ｂに対応した第２の検出
部８４ｂにも、第１７図に示した回路構成で、第２の感
圧抵抗体４５ｂ１第２の電源８６ｂ、第２の抵抗８７ｂ
、第２の発振回路８８ｂ１第２のアンプ８９ｂ１第２の
スピーカ９０ｂがそれぞれ接続されている。そして、第
１８図に示すように前記第１の検出部８４ａ１および第
２の検出部８４ｂは皮下端子本体８３の上部面から上方
へ突出し、さらに、第１の感圧抵抗体８５ａ、第２の感
圧抵抗体８５ｂを上面とした構成になっている。また、
前記第１の発振回路８８ａと第２の発振回路８８ｂはそ
れぞれ異なる周波数で発振されるように構成されている
。したがって、第１のスピーカ９０ａと第２のスピーカ
９０ｂは異なる音を生体外に送り出し、各針入部６９ａ
、６９ｂを別々に判別することができることとなる。そ
の他、この皮下端子の構成は前記第５の実施例のものと
同じである。Similarly, the second detection unit 84b corresponding to the second injection hole 68b has the circuit configuration shown in FIG. 87b
, a second oscillation circuit 88b1, a second amplifier 89b1, and a second speaker 90b are connected respectively. As shown in FIG. 18, the first detection section 84a1 and the second detection section 84b protrude upward from the upper surface of the subcutaneous terminal main body 83, and furthermore, the first pressure sensitive resistor 85a and the second detection section 84b protrude upward from the upper surface of the subcutaneous terminal main body 83. The configuration is such that the pressure sensitive resistor 85b is the top surface. Also,
The first oscillation circuit 88a and the second oscillation circuit 88b are configured to oscillate at different frequencies. Therefore, the first speaker 90a and the second speaker 90b send out different sounds outside the living body, and each needle insertion part 69a
, 69b can be determined separately. In other respects, the configuration of this subcutaneous terminal is the same as that of the fifth embodiment.
しかして、このように構成された皮下端子は前記第５の
実施例で述べたと同様にして使用される。Thus, the subcutaneous terminal constructed in this manner is used in the same manner as described in the fifth embodiment.
すなわち、生体皮膚組織６１の下部に埋入された皮下端
子本体８３の各注入孔６８ａ、６８ｂの位置確認および
判別は、まず、指等により生体皮膚組織６１を介し、各
注入孔６８ａ、６８ｂの近傍にそれぞれ設けられ、皮下
端子本体８３の上部から突き出した各検出部８４ ａ、
８４ｂを押圧する。That is, to confirm and distinguish the positions of the injection holes 68a and 68b of the subcutaneous terminal main body 83 embedded in the lower part of the living body skin tissue 61, first, use a finger or the like to insert the injection holes 68a and 68b through the living body skin tissue 61. Each detection portion 84 a is provided nearby and protrudes from the upper part of the subcutaneous terminal main body 83;
Press 84b.
たとえば、第１の検出部８４ａである場合には抑圧によ
る圧力により感圧抵抗体８５ａの抵抗が下がり、第１７
図で示した電気回路に電流が流れる。For example, in the case of the first detection section 84a, the resistance of the pressure-sensitive resistor 85a decreases due to the pressure caused by the suppression, and the
A current flows through the electrical circuit shown in the diagram.
そして、第１の発振回路８８ａから発振信号が出され、
この信号はアンプ８９ａによって増幅され、第１のスピ
ーカ９０ａから音が生体外へ向けて放出される。これに
より術者はこの音の種類を耳で確認することができる。Then, an oscillation signal is output from the first oscillation circuit 88a,
This signal is amplified by the amplifier 89a, and the sound is emitted outside the living body from the first speaker 90a. This allows the operator to confirm the type of sound by ear.
第２の検出部８４ｂの場合も同様である。また、前述の
通り、各発振回路８８ａ、８８ｂは異なる周波数が発振
されるようになっており、第１の検出部８４ａ側を押圧
したときと第２の検出部８４ｂ側を押圧したときでは、
それぞれ音色が異なる音が生体外へ放出されるため、生
体外より両者の音を聞き比べることにより、各注入孔６
８ａ、６８ｂの位置確認および判別が可能となる。The same applies to the second detection section 84b. Furthermore, as described above, each oscillation circuit 88a, 88b is configured to oscillate at a different frequency, and when the first detection section 84a side is pressed and when the second detection section 84b side is pressed,
Since sounds with different tones are emitted outside the living body, by comparing the two sounds from outside the living body, each injection hole 6
It becomes possible to confirm and distinguish the positions of 8a and 68b.
そして、第５の実施例で述べたように使用すれば、末期
肝臓癌患者への抗癌剤の注入等に使用することが可能で
ある。If used as described in the fifth embodiment, it can be used for injecting anti-cancer drugs into terminal stage liver cancer patients.
このように構成された皮下端子は、各注入孔６８’ａ、
６８ｂの近傍にそれぞれ対応した検出部８４ａ、８４ｂ
を設けているため、生体外より指等で生体皮膚組織６１
を介し、各検出部８４ａ、８４ｂを押圧することで、生
体外には各検出部８４ａ、８４ｂによって異なる音色の
音が出されることにより、生体外より容品に各注入孔６
８ａ、６８ｂの位置確認、判別が可能となる。この他に
前記第５の実施例の場合と同様な作用効果を奏する。The subcutaneous terminal configured in this way has each injection hole 68'a,
Detectors 84a and 84b respectively corresponding to the vicinity of 68b
Since the skin tissue 61 of the living body is provided with a
By pressing each of the detection parts 84a and 84b through the body, each detection part 84a and 84b produces sounds of different tones outside the living body.
It becomes possible to confirm and distinguish the positions of 8a and 68b. In addition to this, the same effects as in the case of the fifth embodiment are achieved.
第１９図ないし第２１図は本発明の第７の実施例を示す
ものである。この実施例の皮下端子は皮下端子本体９１
に設けた穴部９０ａ、９０ｂに告知手段としてそれぞれ
硬度の異なる第１の検出部材９２ａと第２の検出部材９
２ｂとを別々に埋入して設置したものである。たとえば
、第１の検出部材９２ａとしては、生体為害性の無いシ
リコーンゴム、ウレタンゴム、たとえばＰＶＡよりなる
高含水ゴム等の弾性の大きな部材が、また、第２の検出
部材９２ｂとしては、生体為害性の無いポリエチレン、
ポリエーテルサルホン、テフロン等のプラスチック、ま
たはアルミナ、ハイドロキシアパタイト、β−ＴＣＰ等
のセラミックまたはチタン、ステンレス、Ｃｏ−Ｃｒ合
金等の金属よりなる、第１の検出部材９２ａより弾性の
小さな部材が用いられている。そして、皮下端子本体９
１の各注入孔６８ａ、６８ｂの近傍に設けられた穴部に
各々埋入され、接若等によって固定されている。その他
の皮下端子本体９１の構成は前記第６の実施例の場合と
同じである。19 to 21 show a seventh embodiment of the present invention. The subcutaneous terminal of this embodiment has a subcutaneous terminal main body 91.
A first detection member 92a and a second detection member 9 having different hardnesses are installed as notification means in holes 90a and 90b provided in the
2b and installed separately. For example, the first detection member 92a may be made of a highly elastic member such as silicone rubber, urethane rubber, or high water content rubber made of PVA, which is not harmful to living organisms, and the second detection member 92b may be a material that is not harmful to living organisms. Sterile polyethylene,
A member having less elasticity than the first detection member 92a is used, which is made of plastic such as polyethersulfone or Teflon, ceramic such as alumina, hydroxyapatite, β-TCP, or metal such as titanium, stainless steel, or Co-Cr alloy. It is being Then, the subcutaneous terminal body 9
The injection holes 68a and 68b of No. 1 are each embedded in a hole provided in the vicinity of each injection hole 68a, 68b, and fixed by fixation or the like. The rest of the structure of the subcutaneous terminal main body 91 is the same as that of the sixth embodiment.
このように構成された皮下端子を用いるには、前記第６
の実施例の場合と同様に、この皮下端子本体９１を生体
皮膚組織６１の下部に埋入する。In order to use the subcutaneous terminal configured in this way, the sixth
As in the case of the embodiment, this subcutaneous terminal main body 91 is embedded under the living body skin tissue 61.
そして、生体外よりその生体内の皮下端子本体９１の各
注入孔６８ａ、６８ｂの位置確認および判別を行なうに
は、前記第６の実施例の場合と同様、指等により生体皮
膚組織６１を介し、各注入孔６８ａ、６８ｂの近傍に各
々設けられ、皮下端子本体９１の上部に突出した各検出
部材９２ａ、９２ｂを押圧する。前述したように第１の
検出部材９２ａは弾性の大きな部材が、第２の検出部材
９２ｂは第１の検出部材９２ａより弾性の小さい材料が
用いられているため、生体外より指等でそれぞれの検出
部材９２ａ、９２ｂを押圧することで、術者は第１の検
出部材９２ａと第２の検出部材９２ｂの判別を行なうこ
とが触診で可能となる。したがって、各検出部材の近傍
に設けた第１の注入孔６８ａと第２の注入孔６８ｂの位
置確認、および判別も可能となる。In order to confirm and distinguish the positions of the injection holes 68a and 68b of the subcutaneous terminal main body 91 in the living body from outside the living body, the injection holes 68a and 68b of the subcutaneous terminal main body 91 in the living body can be confirmed and distinguished by using a finger or the like through the living body's skin tissue 61, as in the case of the sixth embodiment. , each of the detection members 92a and 92b, which are provided near the injection holes 68a and 68b and protrudes from the upper part of the subcutaneous terminal body 91, is pressed. As mentioned above, the first detection member 92a is made of a material with greater elasticity, and the second detection member 92b is made of a material with less elasticity than the first detection member 92a. By pressing the detection members 92a and 92b, the operator can distinguish between the first detection member 92a and the second detection member 92b by palpation. Therefore, it is also possible to confirm and distinguish the positions of the first injection hole 68a and the second injection hole 68b provided near each detection member.
このように構成された皮下端子本体９１は、各注入孔６
８ａ、６８ｂの近傍にそれぞれ対応した検出部材９２ａ
、９２ｂが設けられ、また、各検出部材９２ａ、９２ｂ
は硬度の異なる材料で構成されているため、生体外より
指等で生体皮膚組織６１を介し、各検出部材９２ａ、９
２ｂ押圧することで、術者は各検出部材９２ａ、９２ｂ
の判別を行なうことができ、したがって、生体外より各
検出部材９２ａ、９２ｂの近傍に設けた、各注入孔６８
ａ、６８ｂの位置確認、判別が可能となる。The subcutaneous terminal main body 91 configured in this way has each injection hole 6
Detection members 92a corresponding to the vicinity of 8a and 68b, respectively
, 92b are provided, and each detection member 92a, 92b
Since the detection members 92a and 9 are made of materials with different hardnesses, each detection member 92a, 9 is
By pressing 2b, the operator can detect each detection member 92a, 92b.
Therefore, each injection hole 68 provided near each detection member 92a, 92b from outside the living body
It becomes possible to confirm and distinguish the positions of a and 68b.
また、検出部材９２ａ、９２ｂの硬度を変えているだけ
なので、前記第６の実施例のものと比べてその構成が簡
単となり、皮下端子の製作が容易となるとともに、電源
等の交換も不要である。Furthermore, since only the hardness of the detection members 92a and 92b is changed, the configuration is simpler than that of the sixth embodiment, making it easier to manufacture the subcutaneous terminal, and eliminating the need to replace the power supply, etc. be.
第２２図および第２３図は本発明の第８の実施例を示す
ものである。この実施例の皮下端子本体９３には、第２
２図で示すように第１の注入孔６８ａと第２の注入孔６
８ｂが設けられるとともに、この近傍にはそれぞれ第１
の検出部９４ａと第２の検出部９４ｂが対応して設けら
れている。また、この第１の検出部９４ａと第２の検出
部９４ｂは第２３図で示すように皮下端子本体９３の上
部に形成した第１の穴部９５ａと第２の穴部９５ｂに別
々に設けられている。つまり、第２３図で示すように、
前記第１の穴部９５ａは第１の検出部９４ａが押し込め
る程深く形成されている。一方、第２の穴部９５ｂはそ
の深さが浅く形成されている。したがって、これに装填
される第２の検出部９４ｂは深く押し込めることができ
ないようになっている。さらに、第１の検出部９４ａが
設けられている第１の穴部９５ａの内部には、ばね９６
が挿入されており、また、第１の検出部９４ａ１第２の
検出部９４ｂは皮下端子本体９３と第２３図で示すよう
に固定されている。その他の皮下端子本体９３の構成は
前記第７の実施例の場合と同じである。FIGS. 22 and 23 show an eighth embodiment of the present invention. The subcutaneous terminal main body 93 of this embodiment includes a second
As shown in FIG. 2, the first injection hole 68a and the second injection hole 6
8b, and a first
A detection section 94a and a second detection section 94b are provided correspondingly. The first detection section 94a and the second detection section 94b are separately provided in a first hole 95a and a second hole 95b formed in the upper part of the subcutaneous terminal body 93, as shown in FIG. It is being In other words, as shown in Figure 23,
The first hole 95a is formed deep enough to allow the first detection section 94a to be inserted therein. On the other hand, the second hole portion 95b is formed to have a shallow depth. Therefore, the second detection section 94b loaded therein cannot be pushed deeply. Furthermore, a spring 96 is provided inside the first hole 95a in which the first detection portion 94a is provided.
are inserted, and the first detection section 94a1 and second detection section 94b are fixed to the subcutaneous terminal main body 93 as shown in FIG. 23. The rest of the structure of the subcutaneous terminal main body 93 is the same as in the seventh embodiment.
このように構成された皮下端子本体９３を用いるには、
前記第７の実施例の場合と同様、皮下端子本体９３を図
示しない生体皮膚組織の下部に埋入する。To use the subcutaneous terminal main body 93 configured in this way,
As in the case of the seventh embodiment, the subcutaneous terminal main body 93 is embedded under the skin tissue of a living body (not shown).
そして、生体外より生体内の皮下端子本体９３の各注入
孔６８ａ、６８ｂの位置確認および判別を行なうには、
前記第６および第７の実施例と同様、指等により生体皮
膚組織を介し、各注入孔６８ａ、６８ｂの近傍に各々設
けられ、皮下端子本体９３上部に突出した各検出部９４
ａ、９４ｂを押圧する。前述したように第１の検出部９
４ａの設けられた穴部９５ａは、第１の検出部５４ａが
押し込める程深い穴がおいており、さらに、中にはばね
９６が挿入されているが、第２の検出部９４ｂの設けら
れた穴部９５ｂは、深さが浅いため、第２の検出部９５
ｂが押し込めないようになっている。よって、生体外よ
り指等で各々の検出部材を押圧することで、第１の検出
部９４ａは弾性を持って中に押し込まれるが、第２の検
出部９４ｂは押し込まれず、術者は第］の検出部９４ａ
と第２の検出部９４ｂの判別を行なうことが可能となる
。したがって、各検出部近傍にある第１の注入孔６８ａ
と第２の注入孔６８ｂの位置確認および判別も可能とな
る。In order to confirm and distinguish the positions of the injection holes 68a and 68b of the subcutaneous terminal main body 93 in the living body from outside the living body,
Similar to the sixth and seventh embodiments, each detection portion 94 is provided near each injection hole 68a, 68b through the living skin tissue with a finger or the like, and protrudes above the subcutaneous terminal main body 93.
a, press 94b. As mentioned above, the first detection unit 9
The hole 95a in which the first detection part 54a is provided is deep enough to allow the first detection part 54a to be inserted therein, and a spring 96 is inserted therein. Since the hole portion 95b has a shallow depth, the second detection portion 95
b cannot be pushed in. Therefore, by pressing each detection member with a finger or the like from outside the living body, the first detection part 94a is pushed inside with elasticity, but the second detection part 94b is not pushed in, and the operator can detection unit 94a of
It becomes possible to perform the determination by the second detection unit 94b. Therefore, the first injection hole 68a near each detection section
It also becomes possible to confirm and distinguish the position of the second injection hole 68b.
そして、第５の実施例で述べたように末期肝臓癌患者へ
の抗癌剤注入等に使用することが可能となる。As described in the fifth embodiment, it can be used for injecting anticancer drugs into patients with terminal liver cancer.
このように構成された皮下端子本体９３は、各注入孔６
８ａ、６８ｂの近傍にそれぞれ対応した検出部９４ａ、
９４ｂが深さの異なる穴部９５ａ。The subcutaneous terminal main body 93 configured in this way has each injection hole 6
Detection units 94a corresponding to the vicinity of 8a and 68b, respectively.
94b is a hole portion 95a having a different depth.
９５ｂに設けられており、さらに、第１の検出部９４ａ
の下部にはばね９６が挿入されているため、生体外より
指等で生体皮膚組織６１を介し、各検出部９４ａ、９４
ｂを押圧することで、術者は各検出部９４ａ、９４ｂの
判別を行なうことができ、したがって、生体外より各検
出部材９４ａ、９４ｂの近傍に設けた、各注入孔６８ａ
、６８ｂの位置確認、判別が可能となる他、前記第７の
実施例と間等の効果を有する。95b, and further includes a first detection section 94a.
Since a spring 96 is inserted in the lower part of the body, each detection part 94a, 94 can be inserted from outside the body using a finger or the like through the body skin tissue 61.
By pressing b, the operator can distinguish between the respective detection members 94a and 94b, and therefore, each injection hole 68a provided near each detection member 94a and 94b from outside the living body.
, 68b, and has other effects similar to those of the seventh embodiment.
なお、第２４図に示すように第１の穴部９７ａ。Note that, as shown in FIG. 24, the first hole portion 97a.
ｆｔ５２の穴部９７ｂをそれぞれ第１の検出部９４ａと
第２の検出部９４ｂが押し込める程深くあけ、各穴部内
にそれぞればね定数の異なった第１のばね９８ａ、第２
のばね９８ｂを挿入するといった構成でも良い。この場
合も同様の作用で前述した効果が得られることになる。The holes 97b of the ft52 are made deep enough to allow the first detection section 94a and the second detection section 94b to be pushed in, respectively, and a first spring 98a and a second spring with different spring constants are inserted into each hole.
A configuration in which a spring 98b is inserted may also be used. In this case as well, the above-mentioned effects can be obtained through the same action.
また、前記第１、第２、第３、第５、第６、第７、第８
の実施例においては、これら皮下端子を末期肝臓癌患者
の延命において適応した場合を示したが、これに限定さ
れることがなく、各種疾患に対して用いることができる
。また、前記実施例では注入部の数が１個と２個の場合
のみ示したが、これに限定するものではなく、各適応に
応じて注入孔を設けてやればよい。In addition, the first, second, third, fifth, sixth, seventh, and eighth
In the example, the case where these subcutaneous terminals were applied to extend the life of a patient with terminal liver cancer was shown, but the present invention is not limited to this, and can be used for various diseases. Further, in the embodiments described above, only cases where the number of injection parts is one and two are shown, but the invention is not limited to this, and injection holes may be provided according to each application.
［発明の効果］
以上説明したように本発明によれば、生体内に埋め込ん
で定置する皮下端子において、上記皮下端子の注入部の
位置を触診、光等による告知手段により生体外から容易
に知ることができる。したがって、各種流体等の注入や
採取を誤りなく安全に行なうことができる。[Effects of the Invention] As explained above, according to the present invention, in a subcutaneous terminal implanted and fixed in a living body, the position of the injection part of the subcutaneous terminal can be easily known from outside the living body by means of notification such as palpation or light. be able to. Therefore, it is possible to safely inject and collect various fluids and the like without making any mistakes.
第１図は本発明の第１の実施例の皮下端子の平面図、第
２図は同じく本発明の第１の実施例の皮下端子の側断面
図、第３図は同じく本発明の第１の実施例の皮下端子の
使用状態図、第４図は本発明の第２の実施例の皮下端子
の１ａ面図、第５図は同じく本発明の第２の実施例の皮
下端子の使用状態の正面断面図、第６図は本発明の第３
の実施例の皮下端子の平面図、第７図は同じく本発明の
第３の実施例の皮下端子の使用状態図、第８図は本発明
の第４の実施例の皮下端子の平面図、第９図は第８図中
Ａ−Ａ線に沿う皮下端子の断面図、第１０図は第４の実
施例における感圧抵抗体の分解斜視図、第１１図は同じ
＜ｔＸＳ４の実施例における電気回路図、第１２図は同
じく本発明の第４の実施例の皮下端子の使用状態の正面
断面図、第１３図は本発明の第５の実施例の皮下端子の
平面図、第１４図は第１３図中Ｂ−Ｂ線に沿う皮下端子
の断面図、第１５図はその第５の実施例の皮下端子の使
用状態図、第１６図は本発明の第６の実施例の皮下端子
の平面図、第１７図はその第６の実施例の電気回路図、
第１８図は第６の実施例の皮下端子の使用状態図、第１
９図は本発明の第７の実施例の皮下端子の平面図、第２
０図はその第７の実施例の皮下端子の使用状態図、第２
１図はその第７の実施例の皮下端子の要部を示す断面図
、第２２図は本発明の第８の実施例の皮下端子の平面図
、第２３図はその第８の実施例の要部を示す断面図、第
２４図はその第８の実施例の変形例を示す断面図である
。
１・・・皮下端子本体、２，３．４・・・注入部、２２
・・・皮下端子本体、２３，２４．２５・・・注入部、
３０・・・突起部、３１，３３．３５・・・注入部、３
２゜３４．３６・・・固定部材、４１−・・・皮下端子
本体、４２・・・注入孔、４３・・・針入部、４５・・
・感圧抵抗体、５１．５２・・・ＬＥＤ、６７・・・皮
下端子本体、６８ａ、６８ｂ・・・注入孔、７４・・・
感圧抵抗体、７５ａ。
７５ｂ・・ＬＥＤ、８３−・・皮下端子本体、８４ａ８
４ｂ・・・検出部、９０ａ、９０ｂ・・・スピーカ、９
１・・・皮下端子本体、９−２ａ、９２ｂ・・・検出部
材、９３・・・皮下端子本体。FIG. 1 is a plan view of a subcutaneous terminal according to a first embodiment of the present invention, FIG. 2 is a side sectional view of a subcutaneous terminal according to a first embodiment of the present invention, and FIG. FIG. 4 is a side view of the subcutaneous terminal according to the second embodiment of the present invention, and FIG. 5 is a diagram showing the use state of the subcutaneous terminal according to the second embodiment of the present invention. 6 is a front sectional view of the third embodiment of the present invention.
FIG. 7 is a plan view of the subcutaneous terminal according to the third embodiment of the present invention, and FIG. 8 is a plan view of the subcutaneous terminal according to the fourth embodiment of the present invention. Fig. 9 is a cross-sectional view of the subcutaneous terminal along the line A-A in Fig. 8, Fig. 10 is an exploded perspective view of the pressure sensitive resistor in the fourth embodiment, and Fig. 11 is the same in the embodiment of Electric circuit diagram, FIG. 12 is a front sectional view of the subcutaneous terminal according to the fourth embodiment of the present invention in use, FIG. 13 is a plan view of the subcutaneous terminal according to the fifth embodiment of the present invention, and FIG. 14 13 is a sectional view of the subcutaneous terminal along the line B-B in FIG. 13, FIG. 15 is a usage state diagram of the subcutaneous terminal of the fifth embodiment, and FIG. 16 is a subcutaneous terminal of the sixth embodiment of the present invention. 17 is an electric circuit diagram of the sixth embodiment,
Fig. 18 is a usage state diagram of the subcutaneous terminal of the sixth embodiment;
FIG. 9 is a plan view of a subcutaneous terminal according to a seventh embodiment of the present invention;
Figure 0 is a usage state diagram of the subcutaneous terminal of the seventh embodiment.
Fig. 1 is a cross-sectional view showing the main parts of a subcutaneous terminal according to the seventh embodiment, Fig. 22 is a plan view of a subcutaneous terminal according to the eighth embodiment of the present invention, and Fig. 23 is a diagram showing the subcutaneous terminal according to the eighth embodiment. FIG. 24 is a sectional view showing a modification of the eighth embodiment. 1... Subcutaneous terminal body, 2, 3.4... Injection part, 22
...Subcutaneous terminal body, 23,24.25...Injection part,
30... Protrusion, 31, 33.35... Injection part, 3
2゜34.36... Fixing member, 41-... Subcutaneous terminal body, 42... Injection hole, 43... Needle insertion part, 45...
・Pressure sensitive resistor, 51.52...LED, 67...subcutaneous terminal body, 68a, 68b...injection hole, 74...
Pressure sensitive resistor, 75a. 75b...LED, 83-...Subcutaneous terminal body, 84a8
4b...Detection section, 90a, 90b...Speaker, 9
1... Subcutaneous terminal body, 9-2a, 92b... Detection member, 93... Subcutaneous terminal body.
Claims (3)
上記皮下端子の注入部の近傍の一部ないし全部に、生体
外表面から指で押圧することで、その注入部の位置を体
外に告知する告知手段を設けたことを特徴とする皮下端
子。(1) In a subcutaneous terminal that is implanted and placed in a living body,
A subcutaneous terminal, characterized in that a part or all of the vicinity of the injection part of the subcutaneous terminal is provided with a notification means for notifying the outside of the body of the position of the injection part by pressing with a finger from the external surface of the living body.
る皮下端子において、上記皮下端子の少なくとも１つの
注入部、もしくはその近傍の一部ないし全部が、生体外
から触診することで各注入部の位置確認を行なえるよう
に、他と異なる形状で構成したことを特徴とする皮下端
子。(2) In a subcutaneous terminal that has multiple injection parts and is implanted and placed in a living body, at least one injection part of the subcutaneous terminal, or a part or all of the vicinity thereof, can be palpated from outside the living body. A subcutaneous terminal characterized by having a different shape from others so that the position of the injection part can be confirmed.
る皮下端子において、上記皮下端子の注入部、もしくは
その近傍にそれぞれ弾性特性の異なる弾性部材を設けた
ことを特徴とする皮下端子。(3) A subcutaneous terminal having a plurality of injection parts and implanted and fixed in a living body, characterized in that elastic members having different elastic properties are provided at or near the injection parts of the subcutaneous terminal. .
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1025184A JPH02191468A (en) | 1988-10-03 | 1989-02-03 | Subcataneous terminal |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63-249391 | 1988-10-03 | ||
| JP24939188 | 1988-10-03 | ||
| JP1025184A JPH02191468A (en) | 1988-10-03 | 1989-02-03 | Subcataneous terminal |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH02191468A true JPH02191468A (en) | 1990-07-27 |
Family
ID=26362780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1025184A Pending JPH02191468A (en) | 1988-10-03 | 1989-02-03 | Subcataneous terminal |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH02191468A (en) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014028145A (en) * | 2008-01-03 | 2014-02-13 | Univ Of Southern California | Implantable drug delivery device, and instrument and method for supplementing device |
| US9050407B2 (en) | 2008-05-08 | 2015-06-09 | Minipumps, Llc | Implantable drug-delivery devices, and apparatus and methods for filling the devices |
| US9603997B2 (en) | 2011-03-14 | 2017-03-28 | Minipumps, Llc | Implantable drug pumps and refill devices therefor |
| US9919099B2 (en) | 2011-03-14 | 2018-03-20 | Minipumps, Llc | Implantable drug pumps and refill devices therefor |
| US10286146B2 (en) | 2011-03-14 | 2019-05-14 | Minipumps, Llc | Implantable drug pumps and refill devices therefor |
| JP2020182679A (en) * | 2019-05-08 | 2020-11-12 | 古河電気工業株式会社 | Medical apparatus, extracorporeal unit, transmission sheet, medical instrument, and position detection method |
| JP2021029935A (en) * | 2019-08-29 | 2021-03-01 | 古河電気工業株式会社 | Medical device, extracorporeal unit, power transmission sheet, and medical equipment |
| JP2022036149A (en) * | 2019-08-29 | 2022-03-04 | 古河電気工業株式会社 | Medical apparatus, extracorporeal unit, power transmission sheet and medical instrument |
| JP2022036151A (en) * | 2019-08-29 | 2022-03-04 | 古河電気工業株式会社 | Medical apparatus, extracorporeal unit, power transmission sheet and medical instrument |
| JP2022036150A (en) * | 2019-08-29 | 2022-03-04 | 古河電気工業株式会社 | Medical apparatus, extracorporeal unit, power transmission sheet and medical instrument |
| JP2022036148A (en) * | 2019-08-29 | 2022-03-04 | 古河電気工業株式会社 | Medical apparatus, extracorporeal unit, power transmission sheet and medical instrument |
| JP2022043223A (en) * | 2019-08-29 | 2022-03-15 | 古河電気工業株式会社 | Medical apparatus, extracorporeal unit, power transmission sheet and medical instrument |
| WO2022102393A1 (en) * | 2020-11-10 | 2022-05-19 | 古河電気工業株式会社 | Medical device, medical equipment component, and medical equipment |
-
1989
- 1989-02-03 JP JP1025184A patent/JPH02191468A/en active Pending
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014028145A (en) * | 2008-01-03 | 2014-02-13 | Univ Of Southern California | Implantable drug delivery device, and instrument and method for supplementing device |
| US9901687B2 (en) | 2008-01-03 | 2018-02-27 | University Of Southern California | Implantable drug-delivery devices, and apparatus and methods for refilling the devices |
| US9050407B2 (en) | 2008-05-08 | 2015-06-09 | Minipumps, Llc | Implantable drug-delivery devices, and apparatus and methods for filling the devices |
| US9987417B2 (en) | 2008-05-08 | 2018-06-05 | Minipumps, Llc | Implantable drug-delivery devices, and apparatus and methods for filling the devices |
| US9603997B2 (en) | 2011-03-14 | 2017-03-28 | Minipumps, Llc | Implantable drug pumps and refill devices therefor |
| US9919099B2 (en) | 2011-03-14 | 2018-03-20 | Minipumps, Llc | Implantable drug pumps and refill devices therefor |
| US10286146B2 (en) | 2011-03-14 | 2019-05-14 | Minipumps, Llc | Implantable drug pumps and refill devices therefor |
| JP2020182679A (en) * | 2019-05-08 | 2020-11-12 | 古河電気工業株式会社 | Medical apparatus, extracorporeal unit, transmission sheet, medical instrument, and position detection method |
| JP2021029935A (en) * | 2019-08-29 | 2021-03-01 | 古河電気工業株式会社 | Medical device, extracorporeal unit, power transmission sheet, and medical equipment |
| WO2021039705A1 (en) * | 2019-08-29 | 2021-03-04 | 古河電気工業株式会社 | Medical device, extracorporeal unit, power transmission sheet, and medical instrument |
| JP2022036149A (en) * | 2019-08-29 | 2022-03-04 | 古河電気工業株式会社 | Medical apparatus, extracorporeal unit, power transmission sheet and medical instrument |
| JP2022036151A (en) * | 2019-08-29 | 2022-03-04 | 古河電気工業株式会社 | Medical apparatus, extracorporeal unit, power transmission sheet and medical instrument |
| JP2022036150A (en) * | 2019-08-29 | 2022-03-04 | 古河電気工業株式会社 | Medical apparatus, extracorporeal unit, power transmission sheet and medical instrument |
| JP2022036148A (en) * | 2019-08-29 | 2022-03-04 | 古河電気工業株式会社 | Medical apparatus, extracorporeal unit, power transmission sheet and medical instrument |
| JP2022043223A (en) * | 2019-08-29 | 2022-03-15 | 古河電気工業株式会社 | Medical apparatus, extracorporeal unit, power transmission sheet and medical instrument |
| EP3998101A4 (en) * | 2019-08-29 | 2022-08-31 | Furukawa Electric Co., Ltd. | Medical device, extracorporeal unit, power transmission sheet, and medical instrument |
| US11554257B2 (en) | 2019-08-29 | 2023-01-17 | Furukawa Electric Co., Ltd. | Medical device, extracorporeal unit, power transmission sheet, and medical instrument |
| WO2022102393A1 (en) * | 2020-11-10 | 2022-05-19 | 古河電気工業株式会社 | Medical device, medical equipment component, and medical equipment |
| CN114828938A (en) * | 2020-11-10 | 2022-07-29 | 古河电气工业株式会社 | Medical device, medical instrument member, and medical instrument |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1962921A2 (en) | Implantable medical device | |
| AU2018200152B2 (en) | Vascular access device and guiding portion | |
| JPH02191468A (en) | Subcataneous terminal | |
| US7347843B2 (en) | Vascular access port with needle detector | |
| JP5769775B2 (en) | Access port and identification method | |
| US9186172B2 (en) | Epidural space locating device | |
| ES2804307T3 (en) | Access port that includes a septum with three projections and a communication device for identification of the septum | |
| KR101887096B1 (en) | Subcutaneous venous access port and apparatus for ejecting drug having the same | |
| JPS61265146A (en) | Embeddable apparatus for long-term injection of substance, especially,treating substance | |
| US20050124980A1 (en) | Port stem marking for catheter placement | |
| US20030009131A1 (en) | Leak detection system and method of using the same | |
| CN107548310B (en) | Epidural space identification and detection device | |
| CN112203706B (en) | Patch delivery device with skin contact sensor | |
| JP2009207925A (en) | Microdevice interface for delivering or withdrawing substance through skin of animal | |
| US20100106097A1 (en) | Drug acceptability indicator | |
| WO2020123832A1 (en) | Medical port locator system and method | |
| KR101559740B1 (en) | Epi check point | |
| AU2020478795A1 (en) | Access needle indication systems for locating and accessing subcutaneous medical devices | |
| KR20110006438A (en) | Guide-wire insertion apparatus for catheter | |
| AU2003221468A1 (en) | Needle insertion sensor | |
| US11484647B2 (en) | Medicinal liquid injection port and medicinal liquid injection device | |
| JP3401779B2 (en) | Biological tissue adhesive dispenser | |
| WO2013146307A1 (en) | Device for injecting drug solution into body | |
| JPH1094601A (en) | Intravenous cannula | |
| JP2013172916A (en) | Catheter kit |